Objective: Hypoxic-ischemic encephalopathy (HIE) is a leading cause of morbidity and mortality in neonates. Therapeutic hypothermia (TH) has improved outcomes and mortality in infants with >36 weeks' gestational age (GA) with moderate-to-severe HIE. There are limited data on the safety and efficacy of TH in preterm infants with HIE. This study describes our experience and examines the safety of TH in neonates with <36 weeks' GA.
Study Design: A single-center, retrospective study of preterm neonates born at <36 weeks' GA with moderate-to-severe HIE and treated with TH, compared to a cohort of term neonates with HIE (≥37 weeks' GA), was conducted. The term cohort was matched for degree of background abnormality on electroencephalogram, sex, inborn versus outborn status, and birth year. Medical records were reviewed for pregnancy and delivery complications, need for transfusion, sedation and antiseizure medications, electroencephalography and imaging findings, and in-hospital mortality.
Results: Forty-two neonates born at <36 weeks' GA with HIE received TH between 2005 and 2022. Data from 42 term neonates were analyzed for comparison. The average GA of the preterm cohort was 34.6 weeks and 39.3 weeks for the term cohort. Apgar scores, degree of acidosis, and need for blood product transfusions were similar between groups. Preterm infants were more likely to require inotropic support (55 vs. 29%, = 0.026) and hydrocortisone (36 vs. 12%, = 0.019) for hypotension. The proportion of infants without evidence of injury on magnetic resonance imaging was similar in both groups: 43 versus 50% in preterm and term infants, respectively. No significant difference was found in mortality between groups.
Conclusion: In this single-center cohort, TH in preterm infants appears to be as safe as in term infants, with no significant increase in intracranial bleeds or mortality. Preterm infants more frequently required inotropes and steroids for hypotension. Further research is needed to determine efficacy of TH in preterm infants.
Key Points: · TH is used off-protocol in preterm infants.. · Preterm and term infants have similar mortality.. · Preterm cohort required more inotropic support..
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-2251-6317 | DOI Listing |
Cureus
December 2024
Pediatric Intensive Care Unit, King Fahad Medical City, Riyadh, SAU.
Background: High-flow nasal cannula (HFNC) therapy has developed as a valuable tool for respiratory support in pediatric critical care. It offers an intermediate level of support between traditional low-flow oxygen and non-invasive ventilation (NIV). Studies suggest its effectiveness in improving oxygen delivery, work of breathing, and secretion clearance.
View Article and Find Full Text PDFExp Clin Transplant
December 2024
>From the Department of Nephrology, Toho University Faculty of Medicine, Tokyo, Japan; and the Department of Urology, Ryukyu University, Okinawa, Japan.
Objectives: This study aimed to determine interventions and identify risk factors for lymphocele formation following kidney transplant.
Materials And Methods: We conducted a retrospective review of 296 adult kidney transplants from 2010 to 2022 to investigate postoperative lymphocele formation. We divided patients into lymphocele cases and nonlymphocele cases.
Pediatr Blood Cancer
January 2025
Department of Pediatric Surgery, Urology and Transplantation, Hôpital Universitaire Necker-Enfants Malades, APHP, Université de Paris Cité, Paris, France.
Background: Ovarian mature teratoma represents the most common benign neoplasm among pediatric germ cell tumors. This study reports the prevalence and characteristics of familial forms identified in a single center over 22 years in order to better understand possible familial predispositions to ovarian teratoma.
Methods: The records of all patients who were surgically treated for ovarian teratoma between 2000 and 2022 were retrospectively reviewed.
Transplant Proc
January 2025
Nephrology Department, Hospital Universitario Cruces, Barakaldo, Spain.
Belatacept was introduced as an immunosuppressant for kidney transplantation in 2010, but its use in Spain remains limited. Since its commercialization, 15 kidney transplant recipients have received immunosuppressive treatment with belatacept at the Cruces University Hospital. This observational and retrospective study analyzes the reasons for switching to belatacept, its impact on kidney function, and the drug's safety profile.
View Article and Find Full Text PDFJ Nurs Res
January 2025
College of Nursing & Health Science, Flinders University, Adelaide, Australia.
Background: Despite an overall decline in serious adverse events in hospitalized patients, approximately one third of inpatient mortality continues to relate to adverse events impacting patients on general wards. The preparedness of nurses, midwives, and nursing assistants (collectively referred to as ward-based staff) to recognize patient deterioration is therefore seen as critical.
Purpose: The aim of this study was to explore ward-based staff perspectives regarding their preparedness to recognize patient deterioration.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!